Previous Close | 1.5500 |
Open | 1.1000 |
Bid | 1.0000 |
Ask | 2.4500 |
Strike | 145.00 |
Expire Date | 2024-12-20 |
Day's Range | 1.1000 - 1.1000 |
Contract Range | N/A |
Volume | |
Open Interest | 24 |
Haemonetics' (HAE) hospital portfolio is evolving and helping to create new opportunities for growth and diversification.
Per Maravai LifeSciences (MRVI) management, this development by TriLink is set to advance nucleic acid-based therapies.
Investors are optimistic about Haemonetics (HAE) led by its strategic focus on establishing leading positions in high-growth markets to generate solid financial returns.